作者
Wolfgang Löscher, Heidrun Potschka
发表日期
2002/4/1
来源
Journal of pharmacology and experimental therapeutics
卷号
301
期号
1
页码范围
7-14
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Epilepsy, one of the most common neurologic disorders, is a major public health issue. Despite more than 20 approved antiepileptic drugs (AEDs), about 30% of patients are refractory to treatment. An important characteristic of pharmacoresistant epilepsy is that most patients with refractory epilepsy are resistant to several, if not all, AEDs, even though these drugs act by different mechanisms. This argues against epilepsy-induced alterations in specific drug targets as a major cause of pharmacoresistant epilepsy, but rather points to nonspecific and possibly adaptive mechanisms, such as decreased drug uptake into the brain by intrinsic or acquired over-expression of multidrug transporters in the blood-brain barrier (BBB). There is accumulating evidence demonstrating that multidrug transporters such as P-glycoprotein (PGP) and members of the multidrug resistance-associated protein (MRP) family are over …
引用总数
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202410284546494042283131233521252224211814144111
学术搜索中的文章